Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Incidence and Burden of the Myelodysplastic Syndromes

    ... despite strong evidence that hypomethylating agents and lenalidomide significantly reduce transfusion burden. Other unmet needs ...

    Research Article last updated 10/14/2015 - 8:44am.

  2. Current and novel therapeutic approaches in myelodysplastic syndromes

    ... the US Food and Drug Administration for its treatment: lenalidomide , 5- azacitidine , and decitabine . These ...

    Research Article last updated 05/26/2015 - 12:13pm.

  3. Pathogenesis of MDS: An Overview of molecular and non-molecular aspects of the disease

    ... of patients with MDS: immunomodulatory agents ( lenalidomide ), and hypomethylating therapy [HMT ( decitabine and ...

    Research Article last updated 05/12/2015 - 9:47am.

  4. Effectiveness of lenalidomide in patients over 75 vs. patients under 75 with RBC transfusion-dependent low/int-1-risk MDS and del5q

    ... report. Abstract # 6522 The FDA approved lenalidomide in 2005 for treatment of lower risk MDS patients (low or ... that a majority of such patients who were treated with lenalidomide achieved sustained independence from RBC transfusions.  Moreover, ...

    Research Review last updated 05/02/2016 - 9:32am.

  5. Lenalidomide in MDS: Where Have We Been and Where Are We Going?

    ... with Ari Giagounidis, Questions asked: What is lenalidomide (also known as Revlimid)? Is lenalidomide considered for treating patients with other sub-types of MDS ...

    LMS Item last updated 06/10/2016 - 1:24pm.

  6. Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?

    ... et al. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or ... outcomes in these patients are needed. Azacitidine and lenalidomide both have meaningful single-agent clinical activity in HR-MDS and ...

    Research Article last updated 06/28/2013 - 1:24pm.

  7. Thrombopoiesis-stimulating agents and myelodysplastic syndromes

    ... therapies, such as azacitidine or lenalidomide . The recombinant human erythropoietin (rHuEPO) ...

    Research Article last updated 03/04/2015 - 10:20am.

  8. More is better: Combination therapies for myelodysplastic syndromes

    ... are currently three FDA-approved medications for MDS; lenalidomide , azacitidine , and decitabine . The role of ...

    Research Article last updated 03/03/2015 - 2:41pm.

  9. Established and novel agents for myelodysplastic syndromes

    ... abnormality or those who fail these initial approaches, lenalidomide may be tried, as can experimental agents. Lower-risk patients ...

    Research Article last updated 03/03/2015 - 1:10pm.

  10. Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease

    ... of patients with MDS: immunomodulatory agents ( lenalidomide ), and hypomethylating therapy [HMT ( decitabine and ...

    Research Article last updated 01/20/2015 - 12:52pm.